(TVTX) – Trader Talk
-
Travere Therapeutics (TVTX) Falls 20% After Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis Fails to Hit Primary Endpoint
-
Travere Therapeutics' (TVTX) FDA Approval of Filspari Includes Warning on Label
Back to TVTX Stock Lookup